Chairman of the 2cureX Board exercises all warrants within the framework of the 2018 incentive program
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

•Nyhetsbrev: Tidningens toppval i superheta försvarssektorn / Satsa på fonderna som andra ratar – bli en vinnare själv

Pressmeddelande

Chairman of the 2cureX Board exercises all warrants within the framework of the 2018 incentive program

MFN Publicerad: 14 Apr 2022 08:45
2cureX

2cureX AB (“2cureX”) hereby announces that the Chairman of the 2cureX Board Povl-Andre’ Bendz has chosen to use his rights to subscribe for shares in 2cureX AB by fully exercising the respective number of warrants in the warrant program 2018/2021.

The now finalized warrant program for Povl-Andre’ included 84.800 warrants. The program was established in 2018 shortly after 2cureX’s listing at Nasdaq First North. The total exercise price of the warrants amounts to SEK 712.230.

The total shareholding of Povl-Andre’ Bendz in 2cureX is now 189.258.

For more information about 2cureX:

Fernando Andreu, Chief Executive Officer
E-mail: [email protected]
Telephone: +45 2279 5399
www.2curex.com

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient’s tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The portfolio of IndiTreat® tests is aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® mCRC Start for first line of therapy, IndiTreat® mCRC Extend and IndiTreat® mCRC Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com

Certified Adviser: Redeye AB, +46 8 121 576 90, [email protected]

Attachments

Chairman of the 2cureX Board exercises all warrants within the framework of the 2018 incentive program

Bifogade filer

Chairman of the 2cureX Board exercises all warrants within the framework of the 2018 incentive programhttps://storage.mfn.se/4fbad246-35d1-4375-9f64-ca191954f402/chairman-of-the-2curex-board-exercises-all-warrants-within-the-framework-of-the-2018-incentive-program.pdf

Nyheter om 2cureX

Läses av andra just nu

Om aktien 2cureX

Senaste nytt